Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Amer H. Zureikat"'
Autor:
Quisette P. Janssen, Jacob L. van Dam, Laura R. Prakash, Deesje Doppenberg, Christopher H. Crane, Casper H.J. van Eijck, Susannah G. Ellsworth, William R. Jarnagin, Eileen M. O’Reilly, Alessandro Paniccia, Marsha Reyngold, Marc G. Besselink, Matthew H.G. Katz, Ching-Wei D. Tzeng, Amer H. Zureikat, Bas Groot Koerkamp, Alice C. Wei
Publikováno v:
Journal of the National Comprehensive Cancer Network, 20(7), 783-791. Cold Spring Publishing LLC
Journal of the National Comprehensive Cancer Network : JNCCN, 20(7), 783-791. Cold Spring Publishing LLC
J Natl Compr Canc Netw
Journal of the National Comprehensive Cancer Network : JNCCN, 20(7), 783-791. Cold Spring Publishing LLC
J Natl Compr Canc Netw
Background: The value of neoadjuvant radiotherapy (RT) after 5-fluorouracil with leucovorin, oxaliplatin, and irinotecan, with or without dose modifications [(m)FOLFIRINOX], for patients with borderline resectable (BR) pancreatic ductal adenocarcinom
Publikováno v:
Journal of the National Comprehensive Cancer Network. 16:1424-1428
Gastrointestinal stromal tumors (GISTs) represent 1% of alimentary tract neoplasms. Up to 90% of GISTs are driven by activating mutations in tyrosine kinase KIT or PDGFRα genes. Imatinib mesylate is a tyrosine kinase inhibitor that has recently been
Autor:
Ahmad Hamad, Aatur D. Singhi, Herbert J. Zeh, Rula Amarin, Nathan Bahary, Kevin McGrath, Amer H. Zureikat
Publikováno v:
Journal of the National Comprehensive Cancer Network. 15:983-988
Overexpression of HER2 protein and amplification of the ERBB2 gene has been observed in various adenocarcinomas, providing a therapeutic target that can be used to extend the survival of a select cohort of patients. Anti-HER2 therapy has been success